gip vs glp-1 The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology The Science Behind Tirzepatide: GLP-1

Finally, while it is important to stay hydrated, drinking fluids in small amounts, more frequently during the day will avoid bloating and nausea that can come with distension of the stomach

Losing muscle mass compromises physical function and metabolic health

"Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries." 2026

These medications have seen an explosion in sales with the approval and off-label use for weight loss, typically resulting in a reduction in body weight of 15-21% when combined with nutrition and exercise

Medicare covers GLP-1s for diabetes but not for obesity